Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Front Immunol ; 11: 1311, 2020.
Article in English | MEDLINE | ID: mdl-32676080

ABSTRACT

Chimeric antigen receptor T cell (CART) therapy, administration of certain T cell-agonistic antibodies, immune check point inhibitors, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) and Toxic shock syndrome (TSS) caused by streptococcal as well as staphylococcal superantigens share one common complication, that is T cell-driven cytokine release syndrome (CRS) accompanied by multiple organ dysfunction (MOD). It is not understood whether the failure of a particular organ contributes more significantly to the severity of CRS. Also not known is whether a specific cytokine or signaling pathway plays a more pathogenic role in precipitating MOD compared to others. As a result, there is no specific treatment available to date for CRS, and it is managed only symptomatically to support the deteriorating organ functions and maintain the blood pressure. Therefore, we used the superantigen-induced CRS model in HLA-DR3 transgenic mice, that closely mimics human CRS, to delineate the immunopathogenesis of CRS as well as to validate a novel treatment for CRS. Using this model, we demonstrate that (i) CRS is characterized by a rapid rise in systemic levels of several Th1/Th2/Th17/Th22 type cytokines within a few hours, followed by a quick decline. (ii) Even though multiple organs are affected, small intestinal immunopathology is the major contributor to mortality in CRS. (iii) IFN-γ deficiency significantly protected from lethal CRS by attenuating small bowel pathology, whereas IL-17A deficiency significantly increased mortality by augmenting small bowel pathology. (iv) RNA sequencing of small intestinal tissues indicated that IFN-γ-STAT1-driven inflammatory pathways combined with enhanced expression of pro-apoptotic molecules as well as extracellular matrix degradation contributed to small bowel pathology in CRS. These pathways were further enhanced by IL-17A deficiency and significantly down-regulated in mice lacking IFN-γ. (v) Ruxolitinib, a selective JAK-1/2 inhibitor, attenuated SAg-induced T cell activation, cytokine production, and small bowel pathology, thereby completely protecting from lethal CRS in both WT and IL-17A deficient HLA-DR3 mice. Overall, IFN-γ-JAK-STAT-driven pathways contribute to lethal small intestinal immunopathology in T cell-driven CRS.


Subject(s)
Coronavirus Infections/pathology , Cytokine Release Syndrome/drug therapy , Interferon-gamma/genetics , Interleukin-17/genetics , Janus Kinase Inhibitors/therapeutic use , Pneumonia, Viral/pathology , Pyrazoles/therapeutic use , Animals , COVID-19 , Cells, Cultured , Coronavirus Infections/drug therapy , Cytokine Release Syndrome/pathology , Cytokine Release Syndrome/prevention & control , Cytokines/blood , Cytokines/immunology , HLA-DR3 Antigen/genetics , Intestine, Small/immunology , Intestine, Small/pathology , Lymphocyte Activation/drug effects , Mice , Mice, Knockout , Nitriles , Pandemics , Pneumonia, Viral/drug therapy , Pyrimidines , T-Lymphocytes, Helper-Inducer/immunology
2.
J Immunol ; 195(10): 4578-82, 2015 Nov 15.
Article in English | MEDLINE | ID: mdl-26447229

ABSTRACT

Plasmacytoid dendritic cells (pDCs) are professional type I IFN producers believed to promote lupus. However, questions exist about whether they function at the same level throughout the course of lupus disease. We analyzed high-purity pDCs sorted from lupus mice. Although pDCs produced a large amount of IFN-α during disease initiation, those sorted from late-stage lupus mice were found to be defective in producing IFN-α. These pDCs expressed an increased level of MHC, suggesting a functional drift to Ag presentation. We examined the potential mechanism behind the defect and identified a novel transcriptional factor, Foxj2, which repressed the expression of several genes in pDCs, but not IFN-α. Dysregulation in pDCs appears to be predisposed, because they exhibited an altered transcriptional profile before the onset of clinical signs. Our results suggest that pDCs do not function the same throughout the disease course and lose the ability to produce IFN-α in late-stage lupus mice.


Subject(s)
Dendritic Cells/immunology , Dendritic Cells/metabolism , Forkhead Transcription Factors/immunology , Interferon-alpha/biosynthesis , Lupus Erythematosus, Systemic/immunology , Animals , Cells, Cultured , Female , Forkhead Transcription Factors/genetics , Interferon-alpha/genetics , Lymphocyte Depletion , Mice , RNA Interference , RNA, Small Interfering
3.
ISME J ; 9(3): 770-81, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25216087

ABSTRACT

It has long been recognized that the mammalian gut microbiota has a role in the development and activation of the host immune system. Much less is known on how host immunity regulates the gut microbiota. Here we investigated the role of adaptive immunity on the mouse distal gut microbial composition by sequencing 16 S rRNA genes from microbiota of immunodeficient Rag1(-/-) mice, versus wild-type mice, under the same housing environment. To detect possible interactions among immunological status, age and variability from anatomical sites, we analyzed samples from the cecum, colon, colonic mucus and feces before and after weaning. High-throughput sequencing showed that Firmicutes, Bacteroidetes and Verrucomicrobia dominated mouse gut bacterial communities. Rag1(-) mice had a distinct microbiota that was phylogenetically different from wild-type mice. In particular, the bacterium Akkermansia muciniphila was highly enriched in Rag1(-/-) mice compared with the wild type. This enrichment was suppressed when Rag1(-/-) mice received bone marrows from wild-type mice. The microbial community diversity increased with age, albeit the magnitude depended on Rag1 status. In addition, Rag1(-/-) mice had a higher gain in microbiota richness and evenness with increase in age compared with wild-type mice, possibly due to the lack of pressure from the adaptive immune system. Our results suggest that adaptive immunity has a pervasive role in regulating gut microbiota's composition and diversity.


Subject(s)
Adaptive Immunity , Gastrointestinal Tract/microbiology , Microbiota , Animals , Bacteria/classification , Bacteria/genetics , Bacteria/isolation & purification , Biodiversity , Gastrointestinal Tract/immunology , Homeodomain Proteins/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Phylogeny , Verrucomicrobia/classification , Verrucomicrobia/growth & development , Verrucomicrobia/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL
...